Unidad Médica Onco-hematológica

Puebla City CP 72530

2 studies enrolling now · 7 studies all time

What they study most

Breast Cancer, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Renal Cell Carcinoma

Studies at this site

• A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer — Recruiting now
• A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) — Recruiting now
• A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer — Running, not enrolling
• ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study — Running, not enrolling
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer — Running, not enrolling
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer — Running, not enrolling
• A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) — Stopped early